

CorNotes

CVI SEMINAR SERIES

The next CVI Seminar will be held on **Thursday, January 18, 2007 at 4:00 pm** in **The Van Kampen Conference Center, Building 110, Room 6294**. Our speaker is:

John Chatham, Ph.D.
Associate Professor of Cell Biology
University of Alabama at Birmingham
Birmingham, AL

The title Dr. Chatham's talk is:

"Increasing Protein O-Glycosylation: A New Paradigm for Metabolic Cardioprotection"

For further information about the CVI Seminar Series, contact Dr. Leanne Cribbs at x72817.

CVI JOURNAL CLUB

January 11.....Ms. Hoefling
 January 25.....Dr. Jeske

CVI Journal Club is held at 12:00 noon in the CVI Research Division Conference Room, Rm 5215. For further information, contact Dr. Ken Byron at x72819.

CARDIOLOGY – CVI RESEARCH DIVISION BASIC SCIENCE SEMINAR

The Cardiology Division and the CVI Research Division are sponsoring a series of joint seminars by Loyola Faculty. The following seminar is scheduled at **7:30 am** in the **Van Kampen Conference Center**:

January 18.....Dr. Kyle Henderson

The title of Dr. Henderson's talk is:

"Coronary Endothelial Function: Effects of Hypercholesterolemia and Exercise Training"

For further information, contact Dr. Samarel at x72821

RED-HF TRIAL

Dr. Alain Heroux of the section of Heart Failure/Transplant is the principal investigator conducting the RED-HF clinical trial on behalf of Amgen.

This is a randomized, placebo-controlled, double-blind, parallel group, multicenter study. Subjects with NYHA Class II, III, or IV, left ventricular ejection fraction < 35%, and hemoglobin > 9.0 g/dL and ≤ 12.0 g/dL will be randomized in a 1:1 ratio to receive subcutaneous (SC) darbepoetin alfa or placebo. (Subjects who are NYHA Class II must have had an unplanned hospital admission or emergency room visit for a cardiovascular reason within 12 months prior to randomization.) Darbepoetin alfa will be administered in discrete, predetermined dose strengths between 20 and 600 µg per administration. The dose of darbepoetin alfa will be titrated to gradually achieve and maintain a hemoglobin concentration of at least 13.0 g/dL, not to exceed 14.5 g/dL. Subjects will be seen and investigational product administered initially Q2W and extended to QM when subjects are stable in the hemoglobin target range. Subjects randomized to placebo will receive volume and dose frequency changes resembling dose changes in subjects receiving darbepoetin alfa. Data will be collected quarterly except endpoint data for adjudication and serious adverse event data which will be collected continuously.

Approximately 3,400 subjects will be enrolled. The study is an event-driven trial and will conclude when approximately 1,450 subjects have experienced an event qualifying as a primary endpoint (after adjudication). It is anticipated that the enrollment period will be approximately 16 months, and the duration of treatment for the last subject enrolled is expected to be approximately 18 months. Subjects will be treated until the study closes, which is expected to occur approximately 34 months after randomization of the first subject. Subjects will be followed for adverse events for at least 30 days after receiving the final investigational product administration except where specified otherwise in the protocol.

For more information or to alert the Heart Failure/Transplant team of potential participants, please contact the project's coordinator, Melissa Hill, at 708-327-2723.

RECENT PUBLICATIONS FROM THE CVI

Erhart MA, Kim T, Crews GM, and Pandya A. The use of unilateral PCR to identify prominent heteroduplexes formed during PCR of the mouse microsatellite locus D17Mit23. *Molecular Biotechnology* 33(1):37-48, 2006.